Davis Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$55.5K Hold
352
– – 0.03% 147
2026
Q2
$55.7K Hold
352
– – 0.03% 158
2026
Q1
$45K Hold
352
– – 0.03% 143
2025
Q4
$42.9K Hold
352
– – 0.03% 146
2025
Q3
$35.3K Buy
+352
New +$31.7K 0.02% 162
2025
Q1
$28.5K Hold
352
– – 0.02% 170
2024
Q4
$31.7K Hold
352
– – 0.03% 164
2024
Q3
$34.8K Hold
352
– – 0.03% 165
2024
Q2
$32.8K Hold
352
– – 0.03% 165
2024
Q1
$33K Hold
352
– – 0.03% 159
2023
Q4
$31.4K Buy
+352
New +$26.1K 0.03% 156
2020
Q2
$39K Hold
352
– – 0.07% 117
2020
Q1
$27K Buy
+352
New +$31.2K 0.06% 133

Other funds holding XBI

Davis Capital Management's XBI Position: Q3 2026 in Review

Davis Capital Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q3 2026 at 352 shares worth $55.5K. The position accounts for 0.03% of the portfolio, ranked #147.

Davis Capital Management first reported a position in XBI in Q1 2020 and has held it in 13 quarters since. The position peaked at $55.7K in Q2 2026. 964 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

  • Davis Capital Management held 352 shares of State Street SPDR S&P Biotech ETF worth $55.5K as of Q3 2026.
  • Davis Capital Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q3 2026.
  • State Street SPDR S&P Biotech ETF made up 0.03% of Davis Capital Management's portfolio in Q3 2026, its #147 holding.
  • Davis Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2020 and has held it in 13 quarters since.
  • Davis Capital Management's State Street SPDR S&P Biotech ETF position peaked at $55.7K in Q2 2026.
  • 964 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.